发明名称 DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION
摘要 Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.
申请公布号 US2016313352(A1) 申请公布日期 2016.10.27
申请号 US201615203616 申请日期 2016.07.06
申请人 DREXEL UNIVERSITY 发明人 BLOCK TIMOTHY M.;COMUNALE MARY ANN;MEHTA ANAND
分类号 G01N33/68 主分类号 G01N33/68
代理机构 代理人
主权项 1. A method for diagnosing a liver pathology in a subject suspected of having the liver pathology comprising: obtaining biological fluid from the subject; contacting said biological fluid with a fucose-binding lectin and allowing said lectin to bind to a protein in said biological fluid, wherein said protein is selected from Hemopexin, HBsAg, hepatitis B viral particle, alpha-1-antichymotrypsin, alpha-1-antichymotrypsin His-Pro-less, Ceruloplasmin, alpha-2-macroglobulin, alpha-2-HS-glycoprotein, Haptoglobin, Fibrinogen gamma chain precursor, immunoglobulin, APO-D, Kininogen, Histidine rich glycoprotein, complement factor 1 precursor, complement factor I heavy chain, complement factor I light chain, Complement C1s, Complement factor B precursor, complement factor B Ba fragment, Complement factor B Bb fragment, Complement C3 precursor, Complement C3 beta chain, Complement C3 alpha chain, C3a anaphylatoxin, Complement, C3b alpha′ chain, Complement C3c fragment, Complement C3dg fragment, Complement C3g fragment, Complement C3d fragment, Complement C3f fragment, Complement C5, Complement C5 beta chain, Complement C5 alpha chain, C5a anaphylatoxin, Complement C5 alpha′ chain, Complement C7, alpha-1 B glycoprotein, B-2-glycoprotein, Vitamin D-binding protein, Inter-alpha-trypsin inhibitor heavy chain H2, Alpha-1B-glycoprotein, Angiotensinogen precursor, Angiotensin-1, Angiotensin-2, Angiotensin-3, GARP protein, beta-2-glycoprotein, Clusterin (Apo J), Integrin alpha-8 precursor glycoprotein, Integrin alpha-8 heavy chain, Integrin alpha-8 light chain, hepatitis C viral particle, and Leucine-rich repeat-containing protein 32 precursor; quantifiably detecting bound lectin in the biological fluid to obtain a detected bound lectin value; and comparing the detected bound lectin value with a reference value for lectin binding on said protein in a comparable biological fluid of subjects without said liver pathology, said detected bound lectin value relative to the reference value being indicative of the presence or absence of said liver pathology, wherein a detected bound lectin value that deviates from said reference value to a statistically significant degree is indicative of the presence of said liver pathology, or comparing the detected bound lectin value with a reference value for lectin binding on said protein in a comparable biological fluid of subjects in which said liver pathology is known to be present, said detected bound lectin value relative to the reference value being indicative of the presence or absence of said liver pathology, wherein a detected bound lectin value that deviates from said reference value to a statistically significant degree is indicative of the absence of said liver pathology.
地址 PHILADELPHIA PA US